Fortune News | Aug 28,2021
Apr 29 , 2023
By Cristina Donini , Doreen Akiyo Yomoah
Over the past three years, the COVID-19 pandemic has dominated headlines and spurred scientific research, with experts around the world focusing resources and any potentially useful technology on the problem.
While the spotlight on COVID-19 has dimmed slightly, it remains a high global priority, sometimes to the detriment of infectious diseases linked to poverty and primarily affecting the Global South. For example, Malaria killed an estimated 619,000 people – most children in Sub-Saharan Africa – in 2021, when there were 247 million cases worldwide.
Malaria is an entirely preventable and treatable disease, and researchers have made great strides on both fronts. In March, for example, the World Health Organization (WTO) recommended two new dual-ingredient insecticide-treated bed nets to protect against malaria-transmitting Anopheles mosquitoes, one with a more lethal cocktail of insecticides and the other able to disrupt mosquito growth and reproduction.
Cost-effective antimalarial medicines are another important tool. In 2021, seasonal malaria chemoprevention was administered to around 45 million children aged three months to five years, who received monthly doses of therapeutic drugs at less than four dollars per person. The recent news of a groundbreaking vaccine, GSK's Mosquirix (also known as RTSS), offers some hope, although the cost is still relatively high, at around 40 dollars a child for the first year.
Despite these efforts, malaria continues to pose a threat to public health.
Even after an investment of 26 billion dollars to tackle the disease in Sub-Saharan Africa, the number of cases increased slightly between 2000 and 2019 (although the number of deaths decreased). New prevention measures – tailored to children, in particular – are needed. Further innovation should take a page from the pandemic playbook: one benefit of the flood of COVID-19 research is that it demonstrated the enormous potential of monoclonal antibodies.
These drugs are laboratory-made copies of the proteins that a person's immune system produces to attack specific foreign invaders. Historically, monoclonal antibodies have been a powerful weapon against cancer and autoimmune diseases such as rheumatoid arthritis and lupus. While not often used as a prophylactic, the deployment of monoclonal antibodies to prevent COVID-19 and the respiratory syncytial virus has shown great promise.
Moreover, their exquisite selectivity enables them to discern between closely related molecular targets, resulting in fewer off-target effects. This makes it a medication with an appropriate safety profile for children (as well as other at-risk populations).
A research group at the United States National Institutes of Health, led by Robert Seder, has identified two antibodies against CSP-1, the malaria parasite's protein, to invade liver cells where it first establishes infection. Blocking CSP-1 should thus prevent infection. The more advanced of the two antibodies, L9LS, is currently being tested for its safety and efficacy in children in Mali and Kenya.
The Mali study assesses its success in a setting of seasonal malaria, whereas the Kenya study focuses on an area where year-round infection is possible.
Monoclonal antibodies could be a game-changer for preventing malaria and advancing the long-sought goal of eradication.
The current generation of antimalarial antibodies has been modified so that a single dose can protect a child for at least three months – possibly longer. The clinical trials will determine the extent and exact duration of protection, and provide useful guidance on how much improvement is needed to achieve a dosage that can be injected once per year.
Although antibodies have a reputation for being expensive, with those used to treat cancer priced at over 20,000 dollars a month in Europe and the US, increasing the potency of this cutting-edge treatment could significantly decrease costs. Some believe an injection as small as one millilitre of the antibody drug being trialled in Mali and Kenya could protect children at the cost of only five to 10 dollars per person.
Demand for monoclonal antibodies primarily comes from high-income countries; Africa accounts for only one percent of global sales. This disparity highlights the need to work with national regulatory agencies to ensure that submitted product data adequately address public health concerns and, in the longer term, involve affected countries in producing these biologics.
Although manufacturing antibodies is a complex and highly regulated process, investing in the technology now would be a boon for developing economies burdened by endemic malaria.
Monoclonal antibodies may be the new frontier in the fight against malaria, but getting the word out won't be easy: stakeholders from government, academia, and industry must come together to coordinate advocacy efforts and raise awareness. (The same groups should encourage the development of these biologics for all infectious diseases.)
We are embarking on a long road: the first generation of antimalarial antibodies will not be deployed until 2027. They offer tremendous promise as one of many weapons to fight this child killer, alongside bed nets, medicines, and emerging vaccines.
The clinical trials will tell us whether this potential can be realized, but we would be wise to begin preparing for success now.
PUBLISHED ON
Apr 29,2023 [ VOL
24 , NO
1200]
Fortune News | Aug 28,2021
Editorial | Aug 12,2023
My Opinion | Aug 28,2021
Fortune News | Mar 02,2024
Radar | Oct 24,2020
Fortune News | Oct 28,2023
Commentaries | Aug 20,2022
Agenda | Oct 22,2022
Sunday with Eden | Jul 01,2023
Photo Gallery | 97457 Views | May 06,2019
Photo Gallery | 89678 Views | Apr 26,2019
My Opinion | 67407 Views | Aug 14,2021
Commentaries | 65844 Views | Oct 02,2021
Editorial | May 02,2024
Feb 24 , 2024 . By MUNIR SHEMSU
Abel Yeshitila, a real estate developer with a 12-year track record, finds himself unable to sell homes in his latest venture. Despite slash...
Feb 10 , 2024 . By MUNIR SHEMSU
In his last week's address to Parliament, Prime Minister Abiy Ahmed (PhD) painted a picture of an economy...
Jan 7 , 2024
In the realm of international finance and diplomacy, few cities hold the distinction that Addis Abeba doe...
Sep 30 , 2023 . By AKSAH ITALO
On a chilly morning outside Ke'Geberew Market, Yeshi Chane, a 35-year-old mother cradling her seven-month-old baby, stands amidst the throng...
May 2 , 2024
For successive generations of Ethiopia's tax authorities, the chore of tax collection...
Apr 27 , 2024
The Prosperity Party (PP) - Prosperitians - is charting a course through treacherous...
Apr 20 , 2024
In a departure from its traditionally opaque practices, the National Bank of Ethiopia...
Apr 13 , 2024
In the hushed corridors of the legislative house on Lorenzo Te'azaz Road (Arat Kilo)...
Apr 28 , 2024
A dire situation unfolds across public universities, where students face the harsh re...
Apr 28 , 2024 . By MUNIR SHEMSU
A European business lobby in Ethiopia issued a scathing review of the tax system last...
Apr 28 , 2024
The Federal Supreme Court has recently ruled in the prolonged commercial dispute surr...
Apr 28 , 2024 . By MUNIR SHEMSU
Transport authorities placed blame on driving schools and vehicle inspection centres...